valproic acid has been researched along with Encephalitis in 10 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Encephalitis: Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition.
Excerpt | Relevance | Reference |
---|---|---|
"Autism spectrum disorder is characterized by a variety of cellular and molecular abnormalities which leads to autism-associated behaviors." | 1.91 | Chronic acetyl-L-carnitine treatment alleviates behavioral deficits and neuroinflammation through enhancing microbiota derived-SCFA in valproate model of autism. ( Roghani, M; Sadr, SS; Sanaeierad, A; Zahedi, E, 2023) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (10.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 4 (40.00) | 2.80 |
Authors | Studies |
---|---|
Vasconcelos Calheiros de Oliveira Costa, G | 1 |
Machado Torres, C | 1 |
Ávila Duarte, J | 1 |
Peixoto Medeiros, AL | 1 |
Muxfeldt Bianchin, M | 1 |
Zhang, J | 1 |
Gan, J | 1 |
Wang, J | 1 |
Zahedi, E | 1 |
Sadr, SS | 1 |
Sanaeierad, A | 1 |
Roghani, M | 1 |
Enshaeieh, M | 1 |
Saadatnia, G | 1 |
Babaie, J | 1 |
Golkar, M | 1 |
Choopani, S | 1 |
Sayyah, M | 1 |
Pradhan, A | 1 |
Jairam, A | 1 |
Kumar, RS | 1 |
Srivastava, A | 2 |
Sreevastava, D | 1 |
Dutta, A | 1 |
Arora, S | 1 |
Bairaria, AK | 1 |
Bhargava, A | 1 |
Trojak, B | 1 |
de la Gastine, B | 1 |
Dollfus, S | 1 |
Chakor, RT | 1 |
Bharote, HS | 1 |
Sinn, DI | 1 |
Kim, SJ | 1 |
Chu, K | 1 |
Jung, KH | 1 |
Lee, ST | 1 |
Song, EC | 1 |
Kim, JM | 1 |
Park, DK | 1 |
Kun Lee, S | 1 |
Kim, M | 1 |
Roh, JK | 1 |
Blindauer, KA | 1 |
Harrington, G | 1 |
Morris, GL | 1 |
Ho, KC | 1 |
Gerstenbrand, F | 1 |
Harrer-Kuhnert, G | 1 |
Mamoli, G | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain[NCT01928849] | Phase 2 | 128 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The S-LANSS is a self-reported version of the Leeds Assessment of Neuropathic Symptoms and Signs pain scale. It aims to differentiate neuropathic pain from somatic or nociceptive pain. We will analyze the change in numeric average pain score during the past week (range from 0-10) from baseline. Higher scores indicate greater pain. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
Intervention | score on a scale (Median) |
---|---|
Cherry Syrup | -2 |
Valproic Acid | -2 |
The primary endpoint is the incidence of chronic pain after surgery. The study team will use the average pain score over the past week as noted on the Self-Reported Leeds Assessment of Neuropathic Symptoms and Signs pain scale (S-LANSS) for the assessment of pain, and define chronic pain as a score greater than or equal to 3. (NCT01928849)
Timeframe: 3 months or time of final adjudication assessment, up to 6 months
Intervention | Participants (Count of Participants) |
---|---|
Cherry Syrup | 37 |
Valproic Acid | 36 |
The BPI short form is a multidimensional patient-completed measure that assesses the sensory component of pain intensity. We will analyze the change in average pain score question (ranges 0-10) and the sum of the 7 interference questions (total range 0-70) from baseline. Higher score indicates greater pain and interference. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
Intervention | score on a scale (Median) | |
---|---|---|
BPI Average Pain Score | BPI interference question sum | |
Cherry Syrup | -2 | -15 |
Valproic Acid | -1 | -7 |
The DVPRS is a pain assessment tool developed by the military in an effort to improve reliability and interpretability of pain assessment in the military population. It has been found to be an effective and valid tool in this population. We will analyze the change in numeric pain response (range 0-10) and the sum of the four supplemental questions (range 0-40) from baseline. Higher scores indicate greater pain and functional limitations. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
Intervention | score on a scale (Median) | |
---|---|---|
DVPRS numeric pain | DVPRS Supplemental Question Sum | |
Cherry Syrup | -2 | -9 |
Valproic Acid | 0 | -4.5 |
The effect of study drug on perioperative analgesic consumption and corresponding analysis of pain/sedation scales. Outcome defined as total opioid consumption (mg) during each 24-hour periods following surgery. (NCT01928849)
Timeframe: Assessments during hospitalization (0-24 hours and 24-48 hours post-surgery)
Intervention | morphine milligram equivalents (Median) | |
---|---|---|
Postoperative hours 0-24 | Postoperative hours 24-48 | |
Cherry Syrup | 59 | 49 |
Valproic Acid | 33 | 45 |
The incidence of neuropathic limb or post-amputation pain sub-types as defined by adjudication classification at each assessment time point. (NCT01928849)
Timeframe: Assessments at enrollment and 3 months or time of final adjudication assessment (up to 6 months)
Intervention | Participants (Count of Participants) | |
---|---|---|
Residual limb pain | Phantom limb | |
Cherry Syrup | 29 | 22 |
Valproic Acid | 31 | 26 |
The RASS is a commonly used, valid and reliable assessment tool for use in hospitalized patients. Validity testing reveals good inter-rater reliability among medical, surgical, and intensive care units. We will analyze the numeric score at each assessment (range -5 (unarousable) to 4 (combative)). (NCT01928849)
Timeframe: during hospitalization (0-24 hours and 24-48 hours post-surgery)
Intervention | score on a scale (Median) | |
---|---|---|
Post-op hours 0-24 | Post-op hours 24-48 | |
Cherry Syrup | 0 | 0 |
Valproic Acid | 0 | 0 |
10 other studies available for valproic acid and Encephalitis
Article | Year |
---|---|
Valproate-Induced Reversible Hemichoreoathetosis in a Patient With Rasmussen Encephalitis.
Topics: Encephalitis; Humans; Inflammation; Magnetic Resonance Imaging; Valproic Acid | 2022 |
A case of GFAP-IgG positivity followed by anti-NMDAR encephalitis.
Topics: Acyclovir; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Autoantibodies | 2022 |
Chronic acetyl-L-carnitine treatment alleviates behavioral deficits and neuroinflammation through enhancing microbiota derived-SCFA in valproate model of autism.
Topics: Acetylcarnitine; Animals; Autism Spectrum Disorder; Autistic Disorder; Encephalitis; Female; Microbi | 2023 |
Valproic Acid Inhibits Chronic
Topics: Animals; Brain; Encephalitis; Humans; Mice; Toxoplasma; Toxoplasmosis; Toxoplasmosis, Animal; Valpro | 2021 |
Posterior reversible encephalopathy syndrome posttransplantation: a case report of possible association with cerebrospinal fluid leak after epidural catheterization.
Topics: Adult; Cerebrospinal Fluid; Creatinine; Encephalitis; Female; Humans; Kidney Transplantation; Living | 2009 |
Valproate-induced encephalopathy related to concurrent antimanic medications.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Drug Interactions; Encephalitis; Female; Humans; Valproic | 2011 |
Topiramate-valproate-induced encephalopathy in migraine.
Topics: Adult; Analgesics; Drug Therapy, Combination; Encephalitis; Fructose; Humans; Male; Migraine Disorde | 2012 |
Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation.
Topics: Animals; Apoptosis Regulatory Proteins; Cell Death; Cerebral Hemorrhage; Chemotaxis, Leukocyte; Dise | 2007 |
Fulminant progression of demyelinating disease after valproate-induced encephalopathy.
Topics: Adult; Anticonvulsants; Brain Stem; Cerebral Cortex; Contraindications; Demyelinating Diseases; Ence | 1998 |
[Augmented indication field for Convulex therapy (author's transl)].
Topics: Adolescent; Adult; Aged; Cerebrovascular Disorders; Child, Preschool; Electroencephalography; Enceph | 1976 |